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Myotubularins deﬁne a large family of proteins conserved through evolution. Several
members are mutated in different neuromuscular diseases including centronuclear my-
opathies and Charcot-Marie-Tooth (CMT) neuropathies, or are linked to a predisposition to
obesity and cancer. While some members have phosphatase activity against the 3-
phosphate of phosphoinositides, regulating the phosphorylation status of PtdIns3P and
PtdIns(3,5)P2 implicated in membrane trafﬁcking and autophagy, and producing PtdIns5P,
others lack key residues in the catalytic site and are classiﬁed as dead-phosphatases.
However, these dead phosphatases regulate phosphoinositide-dependent cellular path-
ways by binding to catalytically active myotubularins. Here we review previous studies on
the molecular regulation and physiological roles of myotubularins. We also used the recent
myotubularins three-dimensional structures to underline key residues that are mutated in
neuromuscular diseases and required for enzymatic activity. In addition, through database
mining and analysis, expression proﬁle and speciﬁc isoforms of the different myotubu-
larins are described in depth, as well as a revisited protein interaction network. Compar-
ison of the interactome and expression data for each myotubularin highlights speciﬁc
protein complexes and tissues where myotubularins should have a key regulatory role.
© 2016 Elsevier Ltd. All rights reserved.Contents
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1. Introduction
Myotubularins constitute a large disease-associated family highly conserved through evolution with similarities to
phosphatases. In humans there are 14 clear paralogs of myotubularins: the ﬁrst identiﬁed was MTM1 followed by 13
myotubularin-related proteins MTMR1 to MTMR13 (Laporte et al., 1996, 2003; Robinson and Dixon, 2006). Among them, 8
proteins are active phosphatases while 6 are catalytically dead, with a functional cooperation between members of these two
classes (Kim et al., 2003; Nandurkar et al., 2003). In addition MTMR14 protein (also named hJUMPY) has been described
(Tosch et al., 2006), however phylogenetic studies and protein domain composition suggested it deﬁnes a close but distinct
protein family, and therefore this protein will not be discussed further in this review. Additional pseudogenes related to
myotubularins also exist (Alonso et al., 2004).
Although active myotubularins have been tentatively classiﬁed as Protein Tyrosine Phosphatases (PTP) based on the
presence of a C(X)5R motif, they are speciﬁc phosphoinositides (PPIn) 3-phosphatases that dephosphorylate the phospha-
tidylinositol-3-monophosphate (PtdIns3P) and PtdIns(3,5)P2 into PtdIns and PtdIns5P, respectively (Blondeau et al., 2000;
Taylor et al., 2000; Tronchere et al., 2004; Walker et al., 2001). Conversely, dead myotubularins share a similar organiza-
tion in domains but lack the phosphatase activity (Cui et al., 1998; Nandurkar et al., 2001). PPIn are lipid second messengers
implicated in a wide range of cellular processes from cell growth and survival to cytoskeleton dynamics (Di Paolo and De
Camilli, 2006; Staiano et al., 2015). More speciﬁcally, PtdIns3P and PtdIns(3,5)P2 regulate membrane trafﬁcking at the
endosomal level and autophagy, which are themost studied and characterized functions of myotubularins (Nicot and Laporte,
2008; Robinson and Dixon, 2006). PtdIns5P is implicated in several cellular processes including oxidative stress signaling,
growth factor signaling and transcriptional regulation (Bulley et al., 2015; Giudici et al., 2016; Gozani et al., 2003; Keune et al.,
2013; Ramel et al., 2011).
Myotubularins have been found in almost all eukaryotes fromyeast tomammals, with few exceptions, such as P. falciparum
(Lecompte et al., 2008). Orthologs for the 14 humanmyotubularins are found in chordates, except in rodents whereMTMR8 is
absent at least inmice and rats. A co-evolution has been observed between active and deadmyotubularins, as well as between
active myotubularins and antagonist kinases (Lecompte et al., 2008); for example MTM1 with the class-III PtdIns 3-kinase
VPS34 (PIK3C3) and its regulator VPS15 (PIK3R4). Why have so many myotubularins been duplicated and conserved?
Indeed, the presence of 14 similar proteins in humans could lead to functional redundancy, however this high evolutionary
pressure suggests that each myotubularin has one or several speciﬁc function(s). This speciﬁcity could be related to tissue
expression or splice isoforms, or particular protein-protein interactions. This speciﬁc point will be developed in this review.
To date, mutations were found in 3 myotubularin genes in monogenic human diseases. MTM1 is mutated in X-linked
centronuclear myopathy (XLCNM, OMIM: 310400) also called myotubular myopathy, characterized by hypotonia at birth, a
very severe and generalized muscle weakness, external ophthalmoplegia and respiratory distress (Jungbluth et al., 2008;
Laporte et al., 1996). Two other myotubularins, MTMR2 (encoding active phosphatase) and MTMR13/SBF2 (dead phospha-
tase), are mutated in Charcot-Marie-Tooth neuropathy type 4B1 (4B1, OMIM: 601382) and 4B2 (CMT4B2, OMIM: 604563),
respectively (Azzedine et al., 2003; Bolino et al., 2000; Senderek et al., 2003). CMT4B1 and 2 are two distinct but close forms of
autosomal recessive demyelinating neuropathy affecting peripheral nerves and leading to pronounced muscular atrophy and
weakness of distal limbs. In addition, several myotubularins are linked tomultifactorial diseases as colorectal, gastric and lung
cancers (MTMR3 and 7) (Hu et al., 2011; Song et al., 2010; Weidner et al., 2016), obesity (MTMR9) (Hotta et al., 2011) and
CreutzfeldteJakob disease (MTMR7) (Sanchez-Juan et al., 2012). The fact that ubiquitously expressed myotubularins are
implicated in different tissue-speciﬁc diseases again indicates that the apparent biochemical redundancy is in fact hiding
tissue-speciﬁc functions.
This review focuses on recent advances concerning 3 main aspects of the myotubularin family: gene expression, protein
interactions and protein structure. Through database mining and analysis, the interaction network of myotubularins is
revisited and integrated, and their expression proﬁles and speciﬁc isoforms are described.2. Myotubularins: protein domains and interactions
Myotubularins are multidomain proteins that share the same central core composed of the PH-GRAM (Pleckstrin Ho-
mology - Glucosyltransferase, Rab-like GTPase Activator and Myotubularins) domain that could bind to PPIn or proteins and
the phosphatase-like domain (Fig. 1A) (Begley et al., 2003; Choudhury et al., 2006; Doerks et al., 2000; Tsujita et al., 2004). In
the 8 active myotubularins (MTM1, MTMR1-4 and 6e8), the catalytic domain contains the consensus C(X)5R signature motif
(Alonso et al., 2004; Zhang et al., 1994). In the 6 phosphatase dead myotubularins (MTMR9-12, MTMR5/Sbf1 and MTMR13/
Sbf2), the absence of enzymatic activity is due to the substitution of catalytically essential residues such as the cysteine in the
consensus motif (Cui et al., 1998; Nandurkar et al., 2003).
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protein interactions, the PH (Pleckstrin homology) (MTMR5 and 13) and FYVE (Fab1-YOTB-Vac1-EEA1) (MTMR3 and 4)
domains can bind PPIn (Itoh and Takenawa, 2002), and the DENN domain (MTMR5 and 13) is involved in small Rab GTPase
regulation (Fabre et al., 2000; Jean et al., 2012; Yoshimura et al., 2010). By combining domain organization and phylogenetics,
6 different subgroups are highlighted, each containing exclusively active or dead members (Fig. 1B). In addition, all myotu-
bularins except MTMR10 contain a coiled-coil (CC) domain that is critical for their homodimerization and/or hetero-
dimerization (Berger et al., 2006; Lorenzo et al., 2006). Dimerization also appears to depend on the PH-GRAM domain (Berger
et al., 2006).
Indeed, all myotubularins except MTMR11 have been shown to interact either with themselves or with other myotubu-
larins (Fig. 1C) (Berger et al., 2006; Gupta et al., 2013; Kim et al., 2003; Lorenzo et al., 2006; Mochizuki and Majerus, 2003;
Nandurkar et al., 2003; Schaletzky et al., 2003; Zou et al., 2009). Within the 14 members, 9 have been reported to form
homodimers; this could enhance the membrane targeting by coupling two PH-GRAM domains (Berger et al., 2003). At least
for MTM1, homo-oligomerization controls its allosteric activity, and in vitro MTM1 incubated with its substrate PtdIns3P
forms a heptamer in the presence of PtdIns5P (Schaletzky et al., 2003). One of the most notable characteristics of this family is
that most heterodimers are formed by a coupling between active and dead phosphatases. For example, MTMR2 forms het-
erodimers with its dead homologs MTMR5/Sbf1, MTMR10, MTMR12 and MTMR13/Sbf2. The fact that mutations in MTMR13
lead to a similar neuropathy (CMT4B) as defects in MTMR2 conﬁrms the physiological importance of dead phosphatases and
heterodimers. MTMR9 interacts with 3 different active myotubularins of the same phylogenic subgroup (MTMR6, 7 and 8)Fig. 1. Human myotubularins: domain organization and interactome. A. Scaled representation of the protein domains of human myotubularins. All myo-
tubularins share the PH-GRAM and phosphatase (active or dead) domains. For each myotubularin, amino acid length of the most described protein isoform is
indicated. B. Classification of myotubularins into 6 subgroups based on protein organization and phylogenetics (indicated by the vertical bars on the left). Active
myotubularins are represented in green and dead myotubularins in red. C. Known protein interactions within the myotubularin family. Published interactions are
in orange while interactions found in databases (Biogrid - the biogrid.org) are in blue. D. List of known interactors for each myotubularin. Published interactors
are represented in orange while interactors found in databases with a minimum MUSEscore of 0,95 (Biogrid and Li et al., 2016) are in blue. Common interactors
and interactors of the same protein family are surrounded and related together by a continuous and stippled line, respectively. Similar interactors found for a
specific myotubularin are not surrounded.
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activity of MTMR2 and both are related tomale infertility due to impaired spermatogenesis (Bolino et al., 2004; Firestein et al.,
2002; Kim et al., 2003). In some heterodimers, such as MTM1-MTMR12, MTMR2-MTMR5 and MTMR2-MTMR13, the dead
myotubularin may regulate the cellular localization of the active member (Gupta et al., 2013; Kim et al., 2003; Nandurkar
et al., 2003). Dead myotubularins appear early in evolution and are conserved in many species (Laporte et al., 2003;
Lecompte et al., 2008). Altogether, this suggests (1) a co-evolution between active and dead myotubularins and (2) that
myotubularins rely on oligomerization for their function since very early in the evolution. Heterodimers can also be formed
between two active members of the same phylogenic subgroup, as for MTMR1-MTMR2, MTMR3-MTMR4, MTMR6-MTMR7
and MTMR7-MTMR8 (Fig. 1C).
Numerous interactors have been identiﬁed for each myotubularin (Fig. 1D) (Biogrid - thebiogrid.org and Intact - http://
www.ebi.ac.uk/intact/) (Agrawal et al., 2014; Berggard et al., 2006; Cao et al., 2007; Cui et al., 1998; Fabre et al., 2000;
Firestein et al., 2000; Jean et al., 2012; Li et al., 2016; Plant et al., 2009; Royer et al., 2013; Rual et al., 2005; Srivastava
et al., 2005; Yu et al., 2013; Zhang et al., 2005). Some myotubularins share common interactors or interactors from the
same protein family. For example, MTMR6 and MTMR8 both interact with SOAT1, a protein localized in the endoplasmic
reticulum, which is also the presumed localization of these myotubularins. MTM1 interacts with desmin and MTMR2 with
neuroﬁlament light chain (NFL), that are two intermediate ﬁlament proteins speciﬁcally found in muscles and neurons,
respectively (Hnia et al., 2011; Previtali et al., 2003). This is consistent with mutations in MTM1 and desmin leading to
myopathies and mutations in MTMR2 and NFL leading to CMT neuropathies (Goldfarb et al., 1998; Mersiyanova et al., 2000).
Another well-represented group of interactors is the Rab family: MTMR1-RAB6B, MTMR6-RAB1B, MTMR5-RAB35 and
MTMR13-RAB21 (Jean et al., 2012; Mochizuki et al., 2013). Rabs constitute a very large GTPase family regulating many steps of
membrane trafﬁcking, one of the main cellular functions in which myotubularins are implicated (Barr, 2013). Of note,
myotubularins implicated in 3 heterodimers share common or similar interactors: MTMR1-MTMR2, MTMR1-MTMR5 and
MTMR2-MTMR10. For example, MTMR1 and MTMR5 heterodimerize and interact with different Rab GTPases (Fig. 1D).3. Myotubularins: tissue expression
To investigate howmyotubularin genes are expressed in human tissues, wemined the Genotype-Tissue Expression (GTEx)
database, which has been built by systematic RNA-sequencing using samples of 51 different tissues from hundreds of donors
and 2 transformed cell types in culture. Fig. 2 shows for each gene the relative expression in all tested tissues, and highlights
inwhich tissue a speciﬁc myotubularin is the most/less expressed. This is not absolute expression, therefore a gene cannot be
directly compared to another for the same tissue. A dendrogram was generated using the Pearson correlation coefﬁcient to
highlight hierarchical clustering of myotubularins sharing similar proﬁles of expression. Whilst this is one of many possible
dendrograms and thus it has to be interpreted cautiously, two main groups of myotubularins can be distinguished based on
expression proﬁles: MTMR1-3-8-11-12-13 (upper branch, Fig. 2), and the others (lower branch). Discriminant tissues be-
tween the two groups are brain (almost all regions), skin, vagina and prostate. This does not seem to be directly related to
phylogenetic classiﬁcation, to active/dead and active/active heterodimers or to myotubularins sharing common interactors.
However, some links can be made. For example, MTMR7 and MTMR9 that form an active/dead heterodimer have the closest
expression proﬁles and are both strongly expressed in brain tissues. A similar link applies to MTM1, MTMR2 and MTMR10,
which have correlated expression patterns: they form two active/dead heterodimers MTM1/MTMR10 and MTMR2/MTMR10,
and MTMR2 and MTMR10 have common interactors (Fig. 1C and D) (Lorenzo et al., 2006).Fig. 2. Myotubularins tissue expression. Heatmap of myotubularin genes relative expression within 51 different tissues underlining in which tissue a specific
myotubularin is the most/least expressed (left panel), and absolute expression in 2 cell types. Expression levels have been obtained by mining the GTEx database
(www.gtexportal.org/home/). Dendrogram highlighting the hierachical clustering of myotubularins (right panel), using the Pearson correlation coefficient and
average linkage.
M.A. Raess et al. / Advances in Biological Regulation 63 (2017) 49e58 53Concerning myotubularins related to monogenic diseases, while MTM1 has a low expression level in striated muscles
compared to other tissues such as nerves, colon or testis, mutations in the MTM1 gene lead to a severe myopathy. Thus, the
MTM1 tissue-speciﬁc function could be explained by interactions with partners that are only expressed in muscle, such as
desmin (Hnia et al., 2011). On the contrary, MTMR2 andMTMR13 are highly expressed in nerves, which is consistent with the
neuropathies observed due to mutations in these genes. In addition, MTMR2 binds the neuronal intermediate ﬁlament NFL
(Previtali et al., 2003), highlighting a potential molecular basis common to different CMT neuropathy forms. A link can be
observed between MTMR2 and MTMR5, known to form heterodimers; they both have a high relative expression level in
testis, and defects of these genes lead to male infertility by impaired spermatogenesis (Bolino et al., 2004; Firestein et al.,
2002), therefore adding weight to the physiological signiﬁcance of this data.
Myotubularins expression levels have also been measured in two cell types, lymphocytes and ﬁbroblasts, that are easily
derived from human cells. These cells could allow diagnosis at the protein level or be dedifferentiated into induced plurip-
otent stem (IPS) cells that could be reprogrammed into speciﬁc cell types, allowing study of the pathocellular mechanisms.
This time, absolute expression levels of all myotubularins are compared (Fig. 2). Some myotubularins, such as MTMR5 or
MTMR2, are well expressed in both lymphocytes and ﬁbroblasts, whereas for other myotubularins ﬁbroblasts show a higher
expression level, as for MTMR13 for which study in these cell types might be more adapted. Therefore, interpreting this data
can be useful in deciding which cell lines should be used for research and diagnostic purposes.
4. Myotubularin: mRNA isoforms
The study of gene expression does not take splicing events into account. Indeed, a speciﬁc gene is often spliced into several
mRNA isoforms that could be translated into different protein isoforms. In this review, we use the term “isoform” to deﬁne a
variant of the same protein ormRNA, and “homologs” for different genes. Fig. 3 summarizes themyotubularinmRNA isoforms
expression within all tissues present in the GTEx database. Only signiﬁcantly expressed mRNA isoforms have been repre-
sented, and color-coded based on their predicted protein product: the main protein isoform from the literature, longer/
shorter protein isoforms, or non-coding mRNA isoforms. For each mRNA isoform, the expression level is indicated as a
percentage of total gene expression.
Interestingly, themainmRNA isoform studied in the literature is not always themost expressed (MTM1,MTMR3,MTMR10,
MTMR11 and MTMR12). For MTMR10, the most expressed isoform encodes only the PH-GRAM; it raises the possibility that
this protein isoform exerts a dominant negative effect on oligomerization of myotubularins or on cellular functions. MTMR2
has 4 well expressed mRNA isoforms: one translated into the main 643 amino acids (aa) protein isoform and the three others
translated into a 571 aa protein isoform lacking the N-terminal extremity before the PH-GRAM (Bolino et al., 2001). The latter
is present in all tissues except brain, and may have a speciﬁc function. In addition, some isoforms are tissue-speciﬁc, as for
MTM1 with 2 isoforms only expressed in skeletal muscle. Corresponding peptides lack a part of the PH-GRAM domain and
could support a muscle-speciﬁc function altered in the MTM1-related myopathy. In total, 10 myotubularins express mRNA
isoforms leading to shorter proteins and MTMR1 displays an isoform predicted to encode a longer protein. These differences
can affect various protein domains as the FYVE domain for MTMR3 and MTMR4 or the DENN domain for MTMR5, and thus
could highly impact on protein conformation or protein-protein/protein-lipid interactions.
For MTM1, MTMR11 and MTMR13, the prevailing mRNA isoforms are non-coding, or the corresponding peptides have not
been identiﬁed yet, questioning the function of such isoforms. Finally, some isoforms described in the literature are not
represented here because they were absent in the GTEx database. This is the case for various MTMR1mRNA isoforms that are
known to be well expressed in some tissues (Buj-Bello et al., 2002).
In the future, it would be important to characterize the cellular activity of these tissue-speciﬁc isoforms, in order to get
insight into their physiological relevance.
5. Myotubularins: protein structure
Between 2003 and 2016, the crystal structures of 4 active myotubularins have been determined: MTMR1 (PDB: 5C16),
MTMR2 (1LW3, 1ZVR, 1M7R and 1ZSQ), MTMR6 (2YFO) and MTMR8 (4YZI) (Begley et al., 2003, 2006; Bong et al., 2016). A
crystal structure of mouse MTMR5 has also be resolved, but only contains the C-terminal PH domain (1V5U). No major
differences have been described between the 4 structures, except for the orientation of the MTMR6 PH-GRAM domain; this
could impact MTMR6 oligomerization properties (Bong et al., 2016). From a 3D point of view, myotubularins are globular
proteins with two main parts: the PH-GRAM domain and the catalytic domain, connected by a linker (Fig. 4A) (Begley et al.,
2003). N-terminal extremities, coiled-coil domains and PDZ binding sites are absent of these structures, presumably because
they are too ﬂexible or cleaved by proteolysis. In addition, the cysteine residue of the catalytic C(X)5R motif has been mutated
into a serine for crystallization, except for MTMR6.
The PH-GRAMdomain consists in 7 b-strands and 1 a-helix. Themain characteristic of the catalytic domain is the substrate
binding pocket that is signiﬁcantly deeper and wider than that of classical tyrosine phosphatases, explaining the unique
speciﬁcity of myotubularins for membrane-embedded PPIn substrates (Fig. 4A) (Begley et al., 2003). Indeed, active myotu-
bularins speciﬁcally hydrolyze the D-3 position of PtdIns3P and PtdIns(3,5)P2, two PPIn with large phosphorylated inositol
headgroups that perfectly ﬁt in the catalytic pocket. The D-3 phosphate is then trapped by its interactionwith the main chain
of 6 residues from the C(X)5R motif loop (on MTMR2 sequence: Cys417, Ser418, Gly420, Trp421, Asp422 and Arg423) (Fig. 4B).
Fig. 3. Myotubularin mRNA isoforms. For each myotubularin indicated on the left, the most expressed isoforms present in the GTEx database are represented as
a percentage of total gene expression. Only the most expressed isoforms are shown. The mRNA isoforms coding for the main published protein isoforms are
indicated in green, shorter isoforms in red and longer isoforms in blue. Several non-coding isoforms indicated in black have been found well expressed, for which
no corresponding peptides have been described yet. The star indicates speciﬁc MTM1 mRNA isoforms in skeletal muscle, the tissue affected in MTM1-related
myopathy. For several myotubularins as MTMR3, MTMR10 and MTMR12, and to a less extend MTMR2, the main expressed isoforms are different than the
published isoforms used for functional characterization of the related proteins; for MTMR11 and MTMR13 the main expressed isoforms are predicted non-coding.
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Fig. 4. The myotubularins protein structure. A. Overall view of the myotubularin structure. The crystal structure of MTMR2 (PDB:1ZSQ) is used as a model, with
a front view and a view rotated at 90 . Domain names and the phosphoinositide substrate (here PtdIns3P) are indicated on the two representations. B. Zoom on
the substrate-binding pocket. Residues forming the C(X)5R loop and other important residues are represented using stick models. Residues affected by missense
mutations in MTM1-linked centronuclear myopathy are colored in yellow. No missense mutations have been found in MTMR2 or MTMR13 genes in the catalytic
pocket. The cysteine residue of the C(X)5R motif is mutated to serine in the structure for crystallization purposes. Hydrogen bonds between the two phosphate
groups in position D1 and D3 of PtdIns3P/PtdIns(3,5)P2 and surrounding residues of the active site are represented by stippled lines.
M.A. Raess et al. / Advances in Biological Regulation 63 (2017) 49e58 55Concerning the catalytic activity, the nucleophile Cys417 residue attacks the phosphorous atom in position D-3 of the PPIn
substrate, forming a phosphoenzyme intermediate, then the aspartic acid (Asp422 in MTMR2) donates a proton to the
released dephosphorylated substrate, before hydrolysis yielding free enzyme and inorganic phosphate (Begley and Dixon,
2005; Begley et al., 2006; Nandurkar and Huysmans, 2002). Myotubularins are different from classical PTPs because the
catalytic aspartate residue lies directly in the catalytic C(X)5R loop and not in a WPD-loop. The D-1 phosphate of the PPIn
interacts with the side chain of two residues from the C(X)5R motif (on MTMR2 sequence: Ser418 and Arg423), but also with
Asn330, which is conserved in all active myotubularins suggesting an important role in PPIn substrate binding. Some other
residues help to maintain the three-dimensional structure of this catalytic pocket, like Arg463 (on MTMR2) that is also
conserved in all myotubularins. A phosphate in position D-4 would generate a steric clash with several residues of the cat-
alytic pocket, excluding PtdIns(3,4)P2 and PtdIns(3,4,5)P3 from potential substrates.
Another consideration for myotubularin substrate speciﬁcity is that active myotubularins are electrostatically polarized
proteins, with one strongly electropositive side containing the catalytic site (Begley et al., 2006). This would create elec-
trostatic interactions between the positively charged face of myotubularins and the negatively charged membranes con-
taining PPIn, contributing to substrate-binding afﬁnity. This electropositive patch around the catalytic pocket seems to be
speciﬁc for active myotubularins, while several dead myotubularins have an electronegative surface, suggesting a poor af-
ﬁnity toward lipid membranes. Furthermore, active myotubularins could bind either membranes or dead-phosphatase ho-
mologs through the same interface.
The three-dimensional structure can also be very useful to understand the effect of disease-associated mutations and
thereby to evaluate the importance of mutated residues for the function or the stability of the protein. The majority of
MTM1, MTMR2 and MTMR13 missense mutations affect residues in the hydrophobic core structure of the PH-GRAM and
catalytic domains, and replace native amino acids by bulkier residues, or decrease van der Waals contacts or alter internal
hydrogen bonds, consequently disrupting the protein core structure. In addition, two clusters of solvent-accessible
M.A. Raess et al. / Advances in Biological Regulation 63 (2017) 49e5856missense mutations at the surface of the MTM1 protein can be observed: the Pro179-Asn180-Arg184 cluster and the
Asp431-Asp433 cluster (numbered in MTM1 sequence) that could be potential binding sites for interactors (Begley et al.,
2003). In the active site, the Ser376, Gly378 and Arg421 (numbered Ser418, Gly420 and Arg463 in MTMR2 structure in
Fig. 4B) are frequent sites of mutations found in MTM1: the Ser376 and Gly378 directly bind the D-3 phosphate of the
PPIn and the Arg421 is a key factor to maintain the position of the catalytic loop. Thus, mutations of these residues would
directly prevent any catalytic activity.
6. Conclusion
Myotubularins deﬁne a large and highly conserved family of proteins with some noteworthy characteristics. They are
classiﬁed in the Protein Tyrosine Phosphatases (PTP) family but have a speciﬁc phosphatase activity against phosphoinosi-
tides. One other feature is the presence of catalytically active and dead phosphatases, where dead myotubularins regulate
their active homologs. Although they are ubiquitously expressed, three myotubularin genes eMTM1,MTMR2 andMTMR13 e
aremutated in tissue-speciﬁc neuromuscular diseases, suggesting tissue-speciﬁc splice isoforms or speciﬁc protein-protein or
protein-lipid interactions.
Future experiments will be needed to address this tissue speciﬁcity. While the function of myotubularins and PPIn sub-
strates and products was well studied in cell systems, their physiological role in vivo is still barely understood. Another key
issue is the pathological mechanism(s) associated to myotubularin-related diseases. Data showed that MTM1-related
myopathy or phenotypes can be rescued in mice and drosophilia by inhibition or muscle-speciﬁc ablation of the class II
PtdIns 3-kinase, pointing to the importance of PPIn regulation by myotubularin (Sabha et al., 2016; Velichkova et al., 2010).
However, the samemouse disease model can also be rescued by expressing a phosphatase inactive MTM1 protein, supporting
that PPIn-unrelated functions of myotubularin are implicated in this pathology (Amoasii et al., 2012). Due to the importance
of myotubularins and PPIn pathways in metabolism and cellular integrity, it is expected that their dysregulation in more
common diseases will be highlighted in the future.Acknowledgements
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